-

New Product Launch: Pharmaceutical Strategies Group Launches Artemetrx Rebate Monitor

Improved oversight of PBM rebates via Artemetrx Rebate Monitor protects the financial interests of health plans

DALLAS--(BUSINESS WIRE)--Artemetrx Rebate Monitor accelerates health plan ability to identify and resolve variances in pharmacy benefit manager (PBM) rebates. Industry insiders designed the newly unveiled tool to revolutionize the approach to rebate guarantees.

Artemetrx Rebate Monitor provides insights to health plans on the adherence to contract terms by the PBM for rebate guarantees. The crucial new tool protects a health plan’s bottom line and relationship with their PBM.

“Rebates are the most critical component of a PBM contract,” said Beth Hebert-Silvia, RPh, Senior Vice President and Health Plan Practice Leader of PSG. “Timely rebate monitoring means health plans can protect financial interests, improve client satisfaction, and increase pharmacy market share.”

Health plans are tapping into Artemetrx Rebate Monitor because it completely overhauls the complex work required to review PBM paid rebates. Artemetrx Rebate Monitor transforms intricate contract terms, conditions, and guarantees into configurable rules applied to actual pharmacy claims data each month.

Artemetrx Rebate Monitor protects the financial interests of health plans via improved rebate oversight. Innovative features include:

  • Dashboards and reporting that quickly identify underperforming rebates by channel or formulary
  • Independent interpretation and calculation of expected rebates by channel
  • Monthly claims ingestion and projection of expected rebates
  • Quarterly ingestion of PBM actual data and ongoing updates
  • Detailed variance reporting between projected and actual rebates paid
  • Access via the Artemetrx web-based software to your data, 24/7

“The speed and efficiency of Artemetrx Rebate Monitor create extraordinary new opportunities to ensure maximum value from rebates,” said Michael Lonergan, RPh, President of PSG. “Innovating is core to our mission. Artemetrx Rebate Monitor is the latest achievement in our more than 25-year legacy of relentless client advocacy.”

Artemetrx is a proprietary industry-leading web-based software for integrated drug management developed by Pharmaceutical Strategies Group (PSG), an EPIC company. Rebate Monitor is the latest in a series of innovations on the Artemetrx platform.

Learn more about how Artemetrx Rebate Monitor is irreversibly shaking up the way rebates are managed: www.psgconsults.com/RebateMonitor

About PSG

Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG’s innovative drug management solutions, including the proprietary data and analytics platform, Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year.

Contacts

Media
Samantha Rideout
Marketing Director, PSG
srideout@psgconsults.com
469.974.6152

Pharmaceutical Strategies Group


Release Versions

Contacts

Media
Samantha Rideout
Marketing Director, PSG
srideout@psgconsults.com
469.974.6152

Social Media Profiles
More News From Pharmaceutical Strategies Group

PSG Announces Results of Highly Comprehensive Pharmacy Benefit Manager Survey

DALLAS--(BUSINESS WIRE)--Pharmaceutical Strategies Group (PSG), an EPIC company, has released its 25th annual 2022 Pharmacy Benefit Manager Customer Satisfaction Report. This extensive report represents the most comprehensive satisfaction research survey in the pharmacy benefit manager (PBM) space, providing unparalleled data and insights. PBM satisfaction rankings in 2022 There was a notable downturn in overall satisfaction levels, as well as in some core measures of general satisfaction such...

PSG Announces New Features Designed to Support Biosimilar Strategy

DALLAS & SAN FRANCISCO--(BUSINESS WIRE)--Pharmaceutical Strategies Group (PSG), an EPIC company, announced an enhancement of its data and analytics platform, Artemetrx®, which will significantly enhance clients’ ability to track and report on the adoption of biosimilar medications. Artemetrx is the leading integrated pharmacy and medical claims platform and is utilized by health plans, pharmacy benefit managers, and employers for drug cost management. While biosimilars have been available in th...

Proprietary State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group

DALLAS--(BUSINESS WIRE)--The Artemetrx Specialty Spend and Trend Report, by PSG, shows biosimilar adoption, but double-digit specialty drug trend persists....
Back to Newsroom